Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with cancer of the colon or rectum, confirmed through laboratory testing of a tissue or cell sample.
• People who have surgical tumour tissue available that can be used to create a personalised cancer DNA tracking test called Signatera.
• People who have completed at least 3 months of a platinum-based chemotherapy combination (given before or after surgery), but have not been treated with a type of chemotherapy called topoisomerase inhibitors as part of their post-surgery treatment.
• People whose CT scans of the chest, abdomen, and pelvis show no visible signs of cancer remaining, with those scans completed within 6 weeks before the first dose of the trial treatment.
• People whose blood tests have detected circulating tumour DNA (tiny fragments of cancer DNA in the bloodstream) within 1 year of finishing adjuvant chemotherapy or after tumour removal surgery, and who are able to begin the trial within 6 weeks of that positive result being confirmed.
• People with rectal cancer who have received a total of at least 3 months of platinum-based combination chemotherapy given around the time of surgery — noting that short-course radiation or standard chemoradiation treatment does not count toward this 3-month minimum.

Who may not be able to join:

• People for whom surgical tumour tissue is not available.
• People who have a history of a lung condition called interstitial lung disease (ILD) or lung inflammation (pneumonitis) that required treatment with steroid medicines, or who show active signs of these conditions on their screening CT scan.

Important: Always verify eligibility with the trial site directly before applying.